Atazanavir modestly increases plasma levels of raltegravir in healthy subjects

被引：67

作者：

Iwamoto, Marian ^{[1
]}

Wenning, Larissa A. ^{[1
]}

Mistry, Goutam C. ^{[1
]}

Petry, Amelia S. ^{[1
]}

Liou, Sarah Y. ^{[1
]}

Ghosh, Kaylan ^{[1
]}

Breidinger, Sheila ^{[1
]}

Azrolan, Neal ^{[1
]}

Gutierrez, Maria J.

Bridson, William E. ^{[2
]}

Stone, Julie A. ^{[1
]}

Gottesdiener, Keith M. ^{[1
]}

Wagner, John A. ^{[1
]}

机构：

[1] Merck, Whitehouse Stn, NJ USA

[2] Covance Clin Res Unit, Madison, WI USA

来源：

CLINICAL INFECTIOUS DISEASES | 2008年 / 47卷 / 01期

关键词：

D O I：

10.1086/588794

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Raltegravir is an HIV integrase inhibitor that is metabolized through glucuronidation by uridine diphosphate glucuronosyltransferase 1A1, and its use is anticipated in combination with atazanavir (a uridine diphosphate glucuronosyltransferase 1A1 inhibitor). Two pharmacokinetic studies of healthy subjects assessed the effect of multiple-dose atazanavir or ritonavir-boosted atazanavir on raltegravir levels in plasma. Atazanavir and atazanavir plus ritonavir modestly increase plasma levels of raltegravir.

引用

页码：137 / 140

页数：4

共 15 条

[1]

*ABB LAB, 2003, NORV RIT PROD CIRC

[2]

*BRIST MYERS SQUIB, 2004, REY AT SULF PROD CIR

[3]

COOPER D, 2007, 14 C RETR OPP INF LO

[4]

GRINSZTEJN B, 2007, 47 INT C ANT AG CHEM

[5] Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial [J].

Grinsztejn, Beatriz ;

Nguyen, Bach-Yen ;

Katlama, Christine ;

Gatell, Jose M. ;

Lazzarin, Adriano ;

Vittecoq, Daniel ;

Gonzalez, Charles J. ;

Chen, Joshua ;

Harvey, Charlotte M. ;

Isaacs, Robin D. .

LANCET, 2007, 369 (9569) :1261-1269

[6] Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects [J].

Iwamoto, M. ;

Wenning, L. A. ;

Petry, A. S. ;

Laethem, M. ;

De Smet, M. ;

Kost, J. T. ;

Merschman, S. A. ;

Strohmaier, K. M. ;

Ramael, S. ;

Lasseter, K. C. ;

Stone, J. A. ;

Gottesdiener, K. M. ;

Wagner, J. A. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) :293-299

[7]

IWAMOTO M, 2006, 46 INT C ANT AG CHEM

[8] Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro/in vivo correlation [J].

Iwamoto, Marian ;

Kassahun, Kelem ;

Troyer, Matthew D. ;

Hanley, William D. ;

Lu, Ping ;

Rhoton, Alisha ;

Pefty, Amelia S. ;

Ghosh, Kalyan ;

Mangin, Eric ;

DeNoia, Emanuel R. ;

Wenning, Larissa A. ;

Stone, Julie A. ;

Gottesdiener, Keith M. ;

Wagner, John A. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (02) :209-214

[9] Metabolism and disposition in humans of raltegravir (MK-0518), an Anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme [J].

Kassahun, Kelem ;

McIntosh, Ian ;

Cui, Donghui ;

Hreniuk, David ;

Merschman, Shelia ;

Lasseter, Kenneth ;

Azrolan, Neal ;

Iwamoto, Marian ;

Wagner, John A. ;

Wenning, Larissa A. .

DRUG METABOLISM AND DISPOSITION, 2007, 35 (09) :1657-1663

[10] Rapid and durable Antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection - Results of a 48-week controlled study [J].

Markowitz, Martin ;

Nguyen, Bach-Yen ;

Gotuzzo, Eduardo ;

Mendo, Fernando ;

Ratanasuwan, Winai ;

Kovacs, Colin ;

Prada, Guillermo ;

Morales-Ramirez, Javier O. ;

Crumpacker, Clyde S. ;

Isaacs, Robin D. ;

Gilde, Lucinda R. ;

Wan, Hong ;

Miller, Michael D. ;

Wenning, Larissa A. ;

Teppler, Hedy .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (02) :125-133

← 1 2 →